The PXR is a drug target for chronic inflammatory liver disease
Open Access
- 1 May 2010
- journal article
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 120 (2-3) , 137-148
Abstract
No abstract availableKeywords
Funding Information
- Wellcome Trust (068879, 087961)
This publication has 60 references indexed in Scilit:
- A functional PXR inhibits portal tract inflammation in a mouse model of cholangiopathyToxicology, 2008
- The impact of pregnane X receptor activation on liver fibrosisBiochemical Society Transactions, 2006
- PPARγ as a new therapeutic target in inflammatory bowel diseasesGut, 2006
- Mutual repression between steroid and xenobiotic receptor and NF- B signaling pathways links xenobiotic metabolism and inflammationJournal of Clinical Investigation, 2006
- Pregnane X Receptor Activators Inhibit Human Hepatic Stellate Cell Transdifferentiation In VitroGastroenterology, 2006
- Peroxisome proliferator activated receptor γ in colonic epithelial cells protects against experimental inflammatory bowel diseaseGut, 2006
- A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γNature, 2005
- Pregnenolone-16α-carbonitrile inhibits rodent liver fibrogenesis via PXR (pregnane X receptor)-dependent and PXR-independent mechanismsBiochemical Journal, 2005
- Regulation of CYP3A4 by the bile acid receptor FXRPharmacogenetics, 2004
- (SWR x SJL)F1 mice: a new model of lupus-like disease.Journal of Experimental Medicine, 1994